Healthcare
Propanc Biopharma, Inc.(PPCB)
Live Price
Offline$1.38
+0.73% today
1Y Change
-98.62%
Window
Jun 23, 2025 โ Jun 9, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +99.0%
- Dividend Yield
- 0.0%
Coverage: 242 bars ยท Jun 23, 2025 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Propanc Biopharma, Inc. (PPCB) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.38 and down 98.6% across the available one-year price window (Jun 23, 2025 โ Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +99.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +99.0%, free cash flow +56.7% with operating margin -217705.1% and ROIC -538.0%. Valuation already assumes a fairly strong business story at price/sales 52.4. Stock Foundry combines PPCB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-217705.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 17, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +99.0%, while operating margin sits near -217705.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 17, 2026 | โ | -4.5% | -4.5% | -45.7% |
2025 Nov 14, 2025 | โ | -2.8% | +4.3% | -3.5% |
2025 Sep 29, 2025 | โ | -7.1% | +8.2% | -19.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PPCB
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PPCB Max Drawdown
-99.47%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PPCB and SPY.
Company Overview
Propanc Biopharma, Inc.
NASDAQ Capital Market
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaรฉn to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
- Leadership
- James Nathanielsz
- IPO Date
- Nov 12, 2012
- Employees
- 1
- Street Address
- 302, 6 Butler Street
- Mailing
- Camberwell, VIC, 3124
- Region
- Camberwell, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 9882 0780
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 52.4
- Price/Book
- 0.1
Growth
- Revenue
- 0.0%
- EPS
- +99.0%
- Free Cash Flow
- +56.7%
Profitability
- Gross Margin
- 0.4%
- Operating Margin
- -217705.1%
- Net Margin
- -220932.3%
- ROE
- -465.2%
- ROIC
- -538.0%
Balance Sheet
- Debt/Equity
- 0.16
- Current Ratio
- 2.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.